The Helen Hayes Hospital Clinical Research Center is one of a select group of sites nationwide where women with osteoporosis have the opportunity to participate in a research study examining new treatment options for osteoporosis.
The IQ Study is evaluating a once-monthly oral medication, which is already approved for the treatment of osteoporosis. The purpose of the study is to evaluate the medication’s effectiveness on bone quality and strength at the hip.
To be eligible for the study, a woman must be postmenopausal for at least twelve months, between the ages of 55 and 80, and already diagnosed with osteoporosis. Individuals who qualify and choose to participate will receive study-related medical care, including physical examinations and study medication, free of charge.
More than eight million women currently have osteoporosis, and millions more are at risk. It is a preventable disease that causes weakening of the bones and a loss of bone mass, resulting in fractures and disability. Helen Hayes Hospital is one of the nation’s leading centers in osteoporosis research.
For additional information, please call study coordinator JoAnn Cruz, RN at 845-786-4802.